Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical (investigational new drug-enabling), and clinical trials that include Phase I and Phase II studies.
Due Date: April 9, 2020, by 3 p.m. Eastern Time
Read more on this opportunity in Funding News.
Global Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.